– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash ...

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its fourth quarter and full-year 2025 financial results on February 26, 2026, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Group 1: Financial Reporting - The financial results for Q4 and full-year 2025 will be released before the market opens on February 26, 2026 [1]. - A live conference call and webcast will be held at 8:00 a.m. ET following the financial results announcement [1]. Group 2: Conference Call Information - To access the conference call, participants can dial (877) 407-8037 for U.S. calls or (201) 689-8037 for international calls, referencing the "Collegium Pharmaceutical Q4 2025 Earnings Call" [2]. - An audio webcast will be available on the Company's website, with a replay accessible approximately two hours after the event [2]. Group 3: Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company, aiming to improve the lives of individuals with serious medical conditions [3]. - The Company has a strong portfolio in responsible pain management medications and a growing neuropsychiatry business, highlighted by Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as the primary growth driver and managing capital deployment in a disciplined manner [3].

Core Viewpoint - Collegium Pharmaceutical, Inc. has successfully closed its inaugural syndicated credit facility of $980 million, which will enhance its financial flexibility and support future business development opportunities [1][2]. Group 1: Credit Facility Details - The credit facility consists of a $580 million initial Term Loan, a $300 million Delayed Draw Term Loan, and a $100 million revolving credit facility, maturing in 2030 [1]. - The initial Term Loan was utilized to repay approximately $581 million of the previous $646 million term loan [1]. - The interest rate for the loans under the Credit Facility is based on the Secured Overnight Financing Rate (SOFR) plus a spread of 2.75% to 3.75%, with the closing rate set at SOFR plus 2.75% [2]. Group 2: Financial Outlook and Strategy - The new credit facility is expected to result in significant annualized interest savings, improving the company's debt terms [2]. - The additional capital will provide the company with the flexibility to pursue long-term value through the expansion and diversification of its product portfolio [2]. - Collegium is focused on growing its commercial portfolio, particularly through its leading product Jornay PM, which is aimed at ADHD treatment [3].

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and is expanding its neuropsychiatry business, particularly with Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy emphasizes the growth of its commercial portfolio, with Jornay PM as the primary growth driver, and aims to deploy capital in a disciplined manner [3].

Core Points - Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary as a publicly traded company by ringing the Nasdaq opening bell on October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD, which is now the fastest growing stimulant medicine for ADHD [2] - Collegium's strategy focuses on growing its commercial portfolio, with Jornay PM as the primary growth driver, while maintaining a disciplined approach to capital deployment [3] Company Overview - Collegium is a diversified biopharmaceutical company dedicated to improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company is headquartered in Stoughton, Massachusetts, and aims to continue making a positive impact in the healthcare community [3]

Core Insights - Collegium Pharmaceutical, Inc. is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market, with a bell-ringing ceremony scheduled for October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM® for ADHD, which is now the fastest growing stimulant medicine for ADHD treatment [2][3] Company Overview - Collegium is focused on building a diversified biopharmaceutical company aimed at improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company's strategy includes expanding its commercial portfolio, with Jornay PM as the primary growth driver, and managing capital deployment in a disciplined manner [3]

Core Viewpoint - Collegium Pharmaceutical, Inc. has authorized a new share repurchase program to buy back up to $150 million in common stock, replacing a previous program that had $65 million remaining [1][2]. Financial Position and Strategy - The company emphasizes its strong financial position, which allows for flexibility in capital allocation and supports shareholder value return [2]. - Since 2021, Collegium has returned $222 million to shareholders through share repurchase programs, including $25 million from an accelerated program initiated in May 2025 [2]. Share Repurchase Program Details - The new share repurchase program is set to run through December 31, 2026, and replaces a previous program that expired on June 30, 2025 [1]. - As of March 31, 2025, Collegium had approximately 32.1 million shares outstanding [3]. Company Overview - Collegium is focused on improving the lives of individuals with serious medical conditions and has a portfolio that includes pain management medications and the recently acquired Jornay PM® for ADHD [4]. - The company's strategy involves growing its commercial portfolio with Jornay PM as a key growth driver and disciplined capital deployment [4].

Financial Performance and Guidance - Collegium reported 2024 sales of $631 million and expects 2025 sales to reach $743 million, representing an +18% increase[16] - The company anticipates 2025 net product revenues in the range of $735 million to $750 million, reflecting an +18% year-over-year growth[22] - Adjusted EBITDA for 2025 is projected to be between $435 million and $450 million, a +10% increase[22] - Adjusted operating expenses for 2025 are expected to be in the range of $220 million to $230 million, a +49% increase[22] Product Portfolio and Market Position - Jornay PM net revenue is expected to exceed $135 million in 2025, representing a +>34% increase from $100.7 million in 2024[40] - The pain portfolio experienced a +5% revenue growth in 2024, while total revenue grew +11%[20] - Q1 2025 pain portfolio product revenues reached $177.8 million, a +23% increase compared to $144.9 million in Q1 2024[32] - Jornay PM prescriptions grew +24% year-over-year in Q1 2025[32] Capital Allocation and Shareholder Value - Collegium initiated a $25 million Accelerated Share Repurchase (ASR) program in May 2025[33] - The company repurchased $222 million worth of shares between 2021 and 2025[47] Debt and Cash Flow - The company had approximately $200 million in cash and marketable securities at the end of Q1 2025[27] - Net debt to adjusted EBITDA stood at approximately 1.5x at the end of Q1 2025[33]

Core Viewpoint - Collegium Pharmaceutical, Inc. has initiated an Accelerated Share Repurchase (ASR) agreement to repurchase $25 million of its common stock as part of a broader $150 million share repurchase program, reflecting a strategic approach to capital allocation while driving revenue growth and returning capital to shareholders [1][2]. Group 1: Financial Performance - In the first quarter of 2025, Collegium reported a 23% year-over-year revenue growth, attributed to strong sales from its pain management portfolio and significant contributions from its ADHD medication, Jornay PM® [2]. - The ASR agreement will initially deliver 692,281 shares to Collegium, based on a closing stock price of $28.89 on May 9, 2025, which represents approximately 80% of the total shares expected to be repurchased [2]. Group 2: Strategic Initiatives - The Board of Directors authorized the $25 million ASR as part of a disciplined capital allocation strategy aimed at sustaining revenue growth while also returning capital to shareholders [2]. - Collegium's strategy includes expanding its commercial portfolio with Jornay PM as a key growth driver and investing in business development while managing debt and share repurchases [2][3]. Group 3: Company Overview - Collegium Pharmaceutical is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, with a strong portfolio in pain management and a recent entry into neuropsychiatry through the acquisition of Jornay PM [3].

Financial Performance - Q1 2025 net product revenues reached $177.8 million, a 23% increase year-over-year compared to $144.9 million in Q1 2024[17,41] - Adjusted EBITDA for Q1 2025 was $95.2 million, a 3% increase compared to $92.4 million in Q1 2024[41] - Adjusted operating expenses for Q1 2025 were $62.2 million, an 80% increase compared to $34.5 million in Q1 2024[41] - The company reaffirms its 2025 financial guidance, projecting net product revenues between $735 million and $750 million, representing an 18% year-over-year increase[43] - The company reaffirms its 2025 financial guidance, projecting adjusted EBITDA between $435 million and $450 million, representing a 10% year-over-year increase[43] - The company reaffirms its 2025 financial guidance, projecting adjusted operating expenses between $220 million and $230 million, representing a 49% year-over-year increase[43] Jornay PM Growth - Jornay PM near-term revenue expectations are projected to be greater than $135 million in 2025, representing a greater than 34% increase from $100.7 million in 2024[33] - Jornay PM prescriptions grew by 24% year-over-year in Q1 2025[17,29] - Market share in branded LA methylphenidate market increased by 22%[29] Capital Deployment and Debt - The company had $197.8 million in cash, cash equivalents, and marketable securities, up $35 million from December 2024[18] - Net debt to adjusted EBITDA at the end of Q1 2025 was approximately 1.5x[18] - A $25 million Accelerated Share Repurchase (ASR) program was authorized by the Board in May 2025[18,48]